Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review
Published Date:Aug 29 2016
Source:Accid Anal Prev. 96:255-270.
Pubmed Central ID:PMC5045819
Funding:R21 HD085122/HD/NICHD NIH HHS/United States
R01 AG050581/AG/NIA NIH HHS/United States
R21 CE001820/CE/NCIPC CDC HHS/United States
U54 GM104942/GM/NIGMS NIH HHS/United States
R01 HD074594/HD/NICHD NIH HHS/United States
Driving under the influence of prescription and over-the-counter medication is a growing public health concern. A systematic review of the literature was performed to investigate which specific medications were associated with increased risk of motor vehicle collision (MVC).
The a priori inclusion criteria were: 1) studies published from English-language sources on or after January 1, 1960, 2) licensed drivers 15 years of age and older, 3) peer-reviewed publications, master's theses, doctoral dissertations, and conference papers, 4) studies limited to randomized control trials, cohort studies, case-control studies, or case-control type studies 5) outcome measure reported for at least one specific medication, 6) outcome measure reported as the odds or risk of a motor vehicle collision. Fourteen databases were examined along with hand-searching. Independent, dual selection of studies and data abstraction was performed.
Fifty-three medications were investigated by 27 studies included in the review. Fifteen (28.3%) were associated with an increased risk of MVC. These included Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone.
Several medications were associated with an increased risk of MVC and decreased driving ability. The associations between specific medication use and the increased risk of MVC and/or affected driving ability are complex. Future research opportunities are plentiful and worthy of such investigation.
Supporting Files:No Additional Files
You May Also Like: